Loading…

Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model

Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not...

Full description

Saved in:
Bibliographic Details
Published in:Small science 2024-09, Vol.4 (9), p.n/a
Main Authors: Solé‐Porta, Anna, Areny‐Balagueró, Aina, Camprubí‐Rimblas, Marta, Fernández Fernández, Elena, O’Sullivan, Andrew, Giannoccari, Rossella, MacLoughlin, Ronan, Closa, Daniel, Artigas, Antonio, Roig, Anna
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page n/a
container_issue 9
container_start_page
container_title Small science
container_volume 4
creator Solé‐Porta, Anna
Areny‐Balagueró, Aina
Camprubí‐Rimblas, Marta
Fernández Fernández, Elena
O’Sullivan, Andrew
Giannoccari, Rossella
MacLoughlin, Ronan
Closa, Daniel
Artigas, Antonio
Roig, Anna
description Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS‐associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready‐to‐be‐used nanomedicine. Poly(lactic‐co‐glycolic acid) nanocapsules (NCs) are investigated as inhalable nanotherapeutics. Stable aerosols can be produced using a commercial nebulizer without any significant alteration of the NCs. In vivo studies with healthy and acute lung injury animals show NCs homogeneously distributed throughout the lungs, arriving at even distal areas. NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance.
doi_str_mv 10.1002/smsc.202400066
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c3cec36f195543fab679f9e939fcd42d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c3cec36f195543fab679f9e939fcd42d</doaj_id><sourcerecordid>3115310717</sourcerecordid><originalsourceid>FETCH-LOGICAL-d3366-1b9838f04444e35fad418f4206152810fa0f2d25834946531656853b4135ca903</originalsourceid><addsrcrecordid>eNpNUUtPAjEQ3hhNJMrVcxPPYN9sj0hQSUBJ0HPT7YOUlBa7u1H89S5giHOZ1zffzOQrijsEhwhC_FBvaz3EEFMIIecXRQ_zshxQSPnlv_i66Nf1poNghtBI4F7xPXXOa29jA15t1Qb_oxqfIlDRgGUbtimqvAePPhlfN9lX7bGbHFimsN_a7DV4VTFplbO3uQb-MArGum0smLdxDWZx03YMy2x18NFrFcAiGRtuiyunQm37f_6m-Hiavk9eBvO359lkPB8YQjgfoEqUpHSQdmYJc8pQVDqKIUcMlwg6BR02mJWECsoZQZzxkpGKIsK0EpDcFLMTr0lqI3fZb7uHZFJeHgspr6XKjdfBSk201YQ7JBijxKmKj4QTVhDhtKHYdFz3J65dTp-trRu5SW2O3fmSINQthyM06lDihPrywe7PKxGUB6XkQSl5VkquFqvJOSO_QC-JQA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115310717</pqid></control><display><type>article</type><title>Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content (ProQuest)</source><creator>Solé‐Porta, Anna ; Areny‐Balagueró, Aina ; Camprubí‐Rimblas, Marta ; Fernández Fernández, Elena ; O’Sullivan, Andrew ; Giannoccari, Rossella ; MacLoughlin, Ronan ; Closa, Daniel ; Artigas, Antonio ; Roig, Anna</creator><creatorcontrib>Solé‐Porta, Anna ; Areny‐Balagueró, Aina ; Camprubí‐Rimblas, Marta ; Fernández Fernández, Elena ; O’Sullivan, Andrew ; Giannoccari, Rossella ; MacLoughlin, Ronan ; Closa, Daniel ; Artigas, Antonio ; Roig, Anna</creatorcontrib><description>Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS‐associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready‐to‐be‐used nanomedicine. Poly(lactic‐co‐glycolic acid) nanocapsules (NCs) are investigated as inhalable nanotherapeutics. Stable aerosols can be produced using a commercial nebulizer without any significant alteration of the NCs. In vivo studies with healthy and acute lung injury animals show NCs homogeneously distributed throughout the lungs, arriving at even distal areas. NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance.</description><identifier>ISSN: 2688-4046</identifier><identifier>EISSN: 2688-4046</identifier><identifier>DOI: 10.1002/smsc.202400066</identifier><language>eng</language><publisher>Weinheim: John Wiley &amp; Sons, Inc</publisher><subject>Aerosols ; Biodistribution ; Drug delivery systems ; Drug dosages ; Drug therapy ; Efficiency ; Growth factors ; Health care ; inhalation ; Inhalers ; lung ; Lungs ; Microscopy ; Mortality ; nanocarriers ; Nanomaterials ; poly(lactic‐co‐glycolic acid) ; Proteins ; vibrating mesh nebulizer</subject><ispartof>Small science, 2024-09, Vol.4 (9), p.n/a</ispartof><rights>2024 The Author(s). Small Science published by Wiley‐VCH GmbH</rights><rights>2024. This work is published under https://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-6464-7573 ; 0000-0002-4085-5324 ; 0000-0002-3164-1607 ; 0000-0002-8029-1017 ; 0000-0003-3797-3095 ; 0000-0002-5823-2731 ; 0000-0002-6129-4087 ; 0000-0001-9611-1781 ; 0000-0002-5434-1260</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3115310717/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3115310717?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,11562,25753,27924,27925,37012,44590,46052,46476,75126</link.rule.ids></links><search><creatorcontrib>Solé‐Porta, Anna</creatorcontrib><creatorcontrib>Areny‐Balagueró, Aina</creatorcontrib><creatorcontrib>Camprubí‐Rimblas, Marta</creatorcontrib><creatorcontrib>Fernández Fernández, Elena</creatorcontrib><creatorcontrib>O’Sullivan, Andrew</creatorcontrib><creatorcontrib>Giannoccari, Rossella</creatorcontrib><creatorcontrib>MacLoughlin, Ronan</creatorcontrib><creatorcontrib>Closa, Daniel</creatorcontrib><creatorcontrib>Artigas, Antonio</creatorcontrib><creatorcontrib>Roig, Anna</creatorcontrib><title>Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model</title><title>Small science</title><description>Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS‐associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready‐to‐be‐used nanomedicine. Poly(lactic‐co‐glycolic acid) nanocapsules (NCs) are investigated as inhalable nanotherapeutics. Stable aerosols can be produced using a commercial nebulizer without any significant alteration of the NCs. In vivo studies with healthy and acute lung injury animals show NCs homogeneously distributed throughout the lungs, arriving at even distal areas. NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance.</description><subject>Aerosols</subject><subject>Biodistribution</subject><subject>Drug delivery systems</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Efficiency</subject><subject>Growth factors</subject><subject>Health care</subject><subject>inhalation</subject><subject>Inhalers</subject><subject>lung</subject><subject>Lungs</subject><subject>Microscopy</subject><subject>Mortality</subject><subject>nanocarriers</subject><subject>Nanomaterials</subject><subject>poly(lactic‐co‐glycolic acid)</subject><subject>Proteins</subject><subject>vibrating mesh nebulizer</subject><issn>2688-4046</issn><issn>2688-4046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpNUUtPAjEQ3hhNJMrVcxPPYN9sj0hQSUBJ0HPT7YOUlBa7u1H89S5giHOZ1zffzOQrijsEhwhC_FBvaz3EEFMIIecXRQ_zshxQSPnlv_i66Nf1poNghtBI4F7xPXXOa29jA15t1Qb_oxqfIlDRgGUbtimqvAePPhlfN9lX7bGbHFimsN_a7DV4VTFplbO3uQb-MArGum0smLdxDWZx03YMy2x18NFrFcAiGRtuiyunQm37f_6m-Hiavk9eBvO359lkPB8YQjgfoEqUpHSQdmYJc8pQVDqKIUcMlwg6BR02mJWECsoZQZzxkpGKIsK0EpDcFLMTr0lqI3fZb7uHZFJeHgspr6XKjdfBSk201YQ7JBijxKmKj4QTVhDhtKHYdFz3J65dTp-trRu5SW2O3fmSINQthyM06lDihPrywe7PKxGUB6XkQSl5VkquFqvJOSO_QC-JQA</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Solé‐Porta, Anna</creator><creator>Areny‐Balagueró, Aina</creator><creator>Camprubí‐Rimblas, Marta</creator><creator>Fernández Fernández, Elena</creator><creator>O’Sullivan, Andrew</creator><creator>Giannoccari, Rossella</creator><creator>MacLoughlin, Ronan</creator><creator>Closa, Daniel</creator><creator>Artigas, Antonio</creator><creator>Roig, Anna</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-VCH</general><scope>24P</scope><scope>WIN</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>M2P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6464-7573</orcidid><orcidid>https://orcid.org/0000-0002-4085-5324</orcidid><orcidid>https://orcid.org/0000-0002-3164-1607</orcidid><orcidid>https://orcid.org/0000-0002-8029-1017</orcidid><orcidid>https://orcid.org/0000-0003-3797-3095</orcidid><orcidid>https://orcid.org/0000-0002-5823-2731</orcidid><orcidid>https://orcid.org/0000-0002-6129-4087</orcidid><orcidid>https://orcid.org/0000-0001-9611-1781</orcidid><orcidid>https://orcid.org/0000-0002-5434-1260</orcidid></search><sort><creationdate>202409</creationdate><title>Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model</title><author>Solé‐Porta, Anna ; Areny‐Balagueró, Aina ; Camprubí‐Rimblas, Marta ; Fernández Fernández, Elena ; O’Sullivan, Andrew ; Giannoccari, Rossella ; MacLoughlin, Ronan ; Closa, Daniel ; Artigas, Antonio ; Roig, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d3366-1b9838f04444e35fad418f4206152810fa0f2d25834946531656853b4135ca903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aerosols</topic><topic>Biodistribution</topic><topic>Drug delivery systems</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Efficiency</topic><topic>Growth factors</topic><topic>Health care</topic><topic>inhalation</topic><topic>Inhalers</topic><topic>lung</topic><topic>Lungs</topic><topic>Microscopy</topic><topic>Mortality</topic><topic>nanocarriers</topic><topic>Nanomaterials</topic><topic>poly(lactic‐co‐glycolic acid)</topic><topic>Proteins</topic><topic>vibrating mesh nebulizer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Solé‐Porta, Anna</creatorcontrib><creatorcontrib>Areny‐Balagueró, Aina</creatorcontrib><creatorcontrib>Camprubí‐Rimblas, Marta</creatorcontrib><creatorcontrib>Fernández Fernández, Elena</creatorcontrib><creatorcontrib>O’Sullivan, Andrew</creatorcontrib><creatorcontrib>Giannoccari, Rossella</creatorcontrib><creatorcontrib>MacLoughlin, Ronan</creatorcontrib><creatorcontrib>Closa, Daniel</creatorcontrib><creatorcontrib>Artigas, Antonio</creatorcontrib><creatorcontrib>Roig, Anna</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Directory of Open Access Journals</collection><jtitle>Small science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Solé‐Porta, Anna</au><au>Areny‐Balagueró, Aina</au><au>Camprubí‐Rimblas, Marta</au><au>Fernández Fernández, Elena</au><au>O’Sullivan, Andrew</au><au>Giannoccari, Rossella</au><au>MacLoughlin, Ronan</au><au>Closa, Daniel</au><au>Artigas, Antonio</au><au>Roig, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model</atitle><jtitle>Small science</jtitle><date>2024-09</date><risdate>2024</risdate><volume>4</volume><issue>9</issue><epage>n/a</epage><issn>2688-4046</issn><eissn>2688-4046</eissn><abstract>Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS‐associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready‐to‐be‐used nanomedicine. Poly(lactic‐co‐glycolic acid) nanocapsules (NCs) are investigated as inhalable nanotherapeutics. Stable aerosols can be produced using a commercial nebulizer without any significant alteration of the NCs. In vivo studies with healthy and acute lung injury animals show NCs homogeneously distributed throughout the lungs, arriving at even distal areas. NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance.</abstract><cop>Weinheim</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/smsc.202400066</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6464-7573</orcidid><orcidid>https://orcid.org/0000-0002-4085-5324</orcidid><orcidid>https://orcid.org/0000-0002-3164-1607</orcidid><orcidid>https://orcid.org/0000-0002-8029-1017</orcidid><orcidid>https://orcid.org/0000-0003-3797-3095</orcidid><orcidid>https://orcid.org/0000-0002-5823-2731</orcidid><orcidid>https://orcid.org/0000-0002-6129-4087</orcidid><orcidid>https://orcid.org/0000-0001-9611-1781</orcidid><orcidid>https://orcid.org/0000-0002-5434-1260</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2688-4046
ispartof Small science, 2024-09, Vol.4 (9), p.n/a
issn 2688-4046
2688-4046
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c3cec36f195543fab679f9e939fcd42d
source Wiley Online Library Open Access; Publicly Available Content (ProQuest)
subjects Aerosols
Biodistribution
Drug delivery systems
Drug dosages
Drug therapy
Efficiency
Growth factors
Health care
inhalation
Inhalers
lung
Lungs
Microscopy
Mortality
nanocarriers
Nanomaterials
poly(lactic‐co‐glycolic acid)
Proteins
vibrating mesh nebulizer
title Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A28%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficient%20Nebulization%20and%20Pulmonary%20Biodistribution%20of%20Polymeric%20Nanocarriers%20in%20an%20Acute%20Lung%20Injury%20Preclinical%20Model&rft.jtitle=Small%20science&rft.au=Sol%C3%A9%E2%80%90Porta,%20Anna&rft.date=2024-09&rft.volume=4&rft.issue=9&rft.epage=n/a&rft.issn=2688-4046&rft.eissn=2688-4046&rft_id=info:doi/10.1002/smsc.202400066&rft_dat=%3Cproquest_doaj_%3E3115310717%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d3366-1b9838f04444e35fad418f4206152810fa0f2d25834946531656853b4135ca903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3115310717&rft_id=info:pmid/&rfr_iscdi=true